Follow-Up in Inflammatory Breast Cancer
There are no changes in the guidelines that cite different treatment in the case of the follow-up of inflammatory breast cancer (IBC) and locally advanced breast cancer. Thus, treatment should adhere to the already established guidelines for locally advanced cancer of metastatic cancer of the breast.
The result of treatment for IBC has improved impressively with the advent of multimodal treatment. Within a period of 20 years, with the introduction of anthracyclines, 5- and 10-year global survival (GS) rates of 40 and 30 % have been reported, respectively. The incorporation of taxanes has been associated with better complete pathological response (cPR) rates and improvement in survival indices. According to the National Cancer Institute’s Surveillance, Epidemiology and End Results (NCI SEER) database, between 1988 and 2001, mean 5-year survival was reported as 40 % for women with IBC against 87 % reported for all cases of breast cancer.
After recurrence, the majority of patients will die. Thus, IBC continues to be one of the most lethal forms of breast cancer.
In this chapter, our purpose is to define the term recurrence, to summarize the general recommendations, to describe the possible clinical condition, the risk factors, the treatment options, their complications, and finally, in the conclusions, to highlight the focus toward which this treatment should be oriented.
KeywordsBreast Cancer Hormone Therapy Zoledronic Acid Aromatase Inhibitor Inflammatory Breast Cancer
- 2.Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at MD Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40(4):321–9.PubMedCrossRefGoogle Scholar
- 3.Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O’Shaughnessy JA, Shen ZZ, Albain KS, ABREAST Investigators. The global breast cancer burden: variations in epidemiology and survival (review). Clin Breast Cancer. 2005;6(5):391–401.PubMedCrossRefGoogle Scholar
- 4.Yoshida T, Takei H, Kurosumi M, Ninomiya J, Ishikawa Y, Hayashi Y, Tozuka K, Oba H, Kawanowa K, Inoue K, Tabei T. True recurrences and new primary tumors have different clinical features in invasive breast cancer patients with ipsilateral breast tumor relapse after breast-conserving treatment. Breast J. 2010;16(2):127–33. Epub 2009 Dec 21.PubMedCrossRefGoogle Scholar
- 6.Segunda Revisión del Consenso Nacional sobre el diagnóstico y tratamiento del Cáncer mamario. Colima; 2005.Google Scholar
- 7.NCCN (National Comprehensive Cancer Network). NCCN practice guidelines in oncology: breast cancer. 2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Mar 2012.
- 8.López-Guerrero JA, Llombart-Cussac A, Noguera R, Navarro S, Pellin A, Almenar S, Vázquez-Alvadalejo C, Llombart-Bosch A. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival. Int J Cancer. 2006;118(7):1743–9.PubMedCrossRefGoogle Scholar
- 14.González-Angulo AM, Morales-Vásquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer (review). Adv Exp Med Biol. 2007;608:122.Google Scholar
- 17.Bonaterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol. 2000;18:3748–57.Google Scholar
- 18.Mouridsen H, Gersanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101–9.PubMedCrossRefGoogle Scholar
- 22.Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386.PubMedCrossRefGoogle Scholar
- 25.Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664.PubMedCrossRefGoogle Scholar
- 27.Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ. Activity of fulvestrant 500 mg versus anastrozole 1mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–5. Epub 2009 Aug 24.PubMedCrossRefGoogle Scholar
- 34.Carrick S, Parker S, Wilcken N, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2005:CD003372.Google Scholar
- 40.Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246–50. Epub 2007 Jun 18.PubMedCrossRefGoogle Scholar
- 41.Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander Jr RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21(15):2889–95.PubMedCrossRefGoogle Scholar
- 42.Thomas ES, Gómez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210–7. Epub 2007 Oct 29.PubMedCrossRefGoogle Scholar
- 43.Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–803. Epub 2005 Sep 19.PubMedCrossRefGoogle Scholar
- 44.Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, García-Sáenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vásquez F, Rodríguez CA, Adrover E, Mel JR, Spanish Breast Cancer Research Group (GEICAM) trial. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8(3):219–25.PubMedCrossRefGoogle Scholar
- 48.Coleman RE. Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new tHER 2apeutic strategy? Eur J Cancer. 2009. doi: 10.1016/j.
- 49.Eidtmann H, Bundred NJ, DeBoer R. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res. 2008;69(Suppl 2). Abstract 44. San Antonio breast cancer symposium.Google Scholar
- 51.Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;(3):CD003474. Epub 2005 Jul 20.Google Scholar
- 53.NCCN Task Force Report. Bone health in cancer care. J Natl Compr Canc Netw. 2009;7 Suppl 3:1–32.Google Scholar